Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Chief Business Officer | November 28, 2016 | November 30, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date November 28, 2016 · Filed November 30, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2026-11-28 | Direct | 500,000 |
Reported balance
After 2016-11-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-28 · Grant · Acquired 500,000 · Balance 500,000 F1: The option vests as to 25% of the option shares on November 28, 2017 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until November 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the option shares on November 28, 2017 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until November 28, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2016 Filed Nov 30, 2016 20:24 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantCommon Stock · Derivative | 500,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000899243-16-034609 · doc4.xml · derivative · entry 1 Knopf Claude · CIK 0001690684 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2026-11-28 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on November 28, 2017 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until November 28, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.